Unknown

Dataset Information

0

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.


ABSTRACT: In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple-negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD-L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial results. The aim of the present review is to collect available evidence on the biological relevance and clinical utility of PD-L1 expression in BC, with particular emphasis on technical aspects, prognostic implications, and predictive value of this promising biomarker. IMPLICATIONS FOR PRACTICE: In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD-L1) in breast cancer has gained increasing interest. This review provides clinicians with an overview of the available clinical evidence regarding PD-L1 as a biomarker in breast cancer, focusing on both data with a possible direct impact on clinic and methodological pitfalls that need to be addressed in order to optimize PD-L1 implementation as a clinically useful tool for breast cancer management.

SUBMITTER: Miglietta F 

PROVIDER: S-EPMC6853089 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.

Miglietta Federica F   Griguolo Gaia G   Guarneri Valentina V   Dieci Maria Vittoria MV  

The oncologist 20190823 11


In the light of recent advances in the immunotherapy field for breast cancer (BC) treatment, especially in the triple-negative subtype, the identification of reliable biomarkers capable of improving patient selection is paramount, because only a portion of patients seem to derive benefit from this appealing treatment strategy. In this context, the role of programmed cell death ligand 1 (PD-L1) as a potential prognostic and/or predictive biomarker has been intensively explored, with controversial  ...[more]

Similar Datasets

| S-EPMC7717727 | biostudies-literature
| S-EPMC4882023 | biostudies-literature
| S-EPMC5601756 | biostudies-literature
| S-EPMC10205737 | biostudies-literature
| S-EPMC5641527 | biostudies-literature
| S-EPMC5448596 | biostudies-literature
| S-EPMC8520884 | biostudies-literature
| S-EPMC8238373 | biostudies-literature
| S-EPMC5601941 | biostudies-literature
| S-EPMC7812012 | biostudies-literature